Blueprint Medicines Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115
Insmed Analyst Ratings
Blueprint Medicines (BPMC) Receives a Hold From Morgan Stanley
Barclays Keeps Their Buy Rating on Insmed (INSM)
Analyst Ratings For Abercrombie & Fitch
Abercrombie & Fitch Analyst Ratings
Lantheus Holdings Analyst Ratings
Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)
Truist Securities Adjusts Price Target on Lantheus Holdings to $141 From $96, Maintains Buy Rating
Lantheus Buy Rating Affirmed Amid Favorable CMS Changes and Strong Market Position
Goldman Sachs Raises Price Target on Insmed to $102 From $74, Maintains Buy Rating
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $102
Goldman Sachs Adjusts Price Target on Sprouts Farmers Market to $89 From $78, Maintains Buy Rating
FTAI Aviation Downgraded at Wolfe Research
Sprouts Farmers Market Analyst Ratings
FTAI Aviation Analyst Ratings
Insmed Analyst Ratings
Truist Financial Sticks to Its Buy Rating for Fluor (FLR)
Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating